미국의 통증 관리용 고주파 절제 기기 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 용도별 및 부문별 예측(2026-2033년)

U.S. Radiofrequency Ablation Devices For Pain Management Market Summary

The U.S. radiofrequency ablation devices for pain management market size was estimated at USD 477.7 million in 2025 and is projected to reach USD 1,029.1 million by 2033, growing at a CAGR of 10.1% from 2026 to 2033. This growth is driven by the rising prevalence of chronic pain conditions such as arthritis and neuropathic disorders, increasing demand for minimally invasive and non-opioid treatment options, and the ongoing shift away from long-term opioid use.

Additionally, advancements in RFA technology, improved clinical outcomes, and growing awareness among both patients and healthcare providers are further supporting market expansion across the U.S.

The rising prevalence of chronic pain conditions in the U.S. is a fundamental driver for the growth of the radiofrequency ablation (RFA) devices for pain management market. Chronic pain, typically defined as pain lasting more than three months, has become one of the most common reasons for healthcare utilization. According to the Centers for Disease Control and Prevention, nearly 24.3% of U.S. adults, approximately 60 million people, experienced chronic pain in 2023, with 8.5% suffering from high-impact chronic pain that significantly limits daily activities. This expanding patient pool directly increases the demand for advanced, minimally invasive pain management solutions such as RFA, which offer targeted and longer-lasting relief compared to conventional therapies.

A key aspect contributing to market growth is the consistent upward trend in chronic pain prevalence over recent years which is linked to aging populations, sedentary lifestyles, obesity, and higher incidence of musculoskeletal and neuropathic disorders. As more patients progress from acute to chronic pain stages, the clinical need shifts toward interventional procedures like RFA, which can disrupt pain signals at the nerve level and reduce long-term dependency on pharmacological treatments. Moreover, chronic pain is strongly associated with functional limitations and reduced quality of life, making effective management a clinical priority. High-impact chronic pain affects over 21 million Americans, often impairing work productivity and daily functioning. This has encouraged healthcare providers to adopt procedures that provide sustained relief with fewer systemic side effects. RFA devices meet this demand by offering precise nerve ablation, particularly in conditions such as osteoarthritis, spinal pain, and cancer-related pain, thereby accelerating their adoption across hospitals and outpatient settings.

U.S. Radiofrequency Ablation Devices For Pain Management Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. radiofrequency ablation devices for pain management market report based on product and end-use:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• RFA Electrodes/ Probes
  • Disposable
  • Reusable
• RFA Cannula (or Needles)
• RFA Generators
• Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Outpatient Facilities
• Others

Table of Contents

Chapter 1. U.S. Radiofrequency Ablation Devices for Pain Management Market: Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. End use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. U.S. Radiofrequency Ablation Devices for Pain Management: Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
  • 2.2.1. Product outlook
  • 2.2.2. End use outlook
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Radiofrequency Ablation Devices for Pain Management: Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Industry Value Chain Analysis
  • 3.3.1. Reimbursement framework
• 3.4. Market Dynamics
  • 3.4.1. Market Driver Analysis
  • 3.4.2. Market Restraint Analysis
• 3.5. U.S. Radiofrequency Ablation Devices for Pain Management Analysis Tools
  • 3.5.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.5.1.1. Supplier Power
    • 3.5.1.2. Buyer Power
    • 3.5.1.3. Substitution Threat
    • 3.5.1.4. Threat of New Entrants
    • 3.5.1.5. Competitive Rivalry
  • 3.5.2. PESTLE Analysis

Chapter 4. U.S. Radiofrequency Ablation Devices for Pain Management: Product Estimates & Trend Analysis

• 4.1. Product Movement Analysis & Market Share, 2025 & 2033
• 4.2. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.3. RFA Electrodes/ Probes
  • 4.3.1. RFA Electrodes/ Probes Market Estimates & Forecasts 2021 to 2033 (USD Million)
  • 4.3.2. Disposable
    • 4.3.2.1. Disposable Market Estimates & Forecasts 2021 to 2033 (USD Million)
  • 4.3.3. Reusable
    • 4.3.3.1. Reusable Market Estimates & Forecasts 2021 to 2033 (USD Million)
• 4.4. RFA Cannula (or Needles)
  • 4.4.1. RFA Cannula (or Needles) Market Estimates & Forecasts 2021 to 2033 (USD Million)
• 4.5. RFA Generators
  • 4.5.1. RFA Generators Market Estimates & Forecasts 2021 to 2033 (USD Million)
• 4.6. Others
  • 4.6.1. Others Market Estimates & Forecasts 2021 to 2033 (USD Million)

Chapter 5. U.S. Radiofrequency Ablation Devices for Pain Management: End Use Estimates & Trend Analysis

• 5.1. End Use Market Share, 2025 & 2033
• 5.2. End Use Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 5.4. Hospitals
  • 5.4.1. Hospitals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 5.5. Outpatient Facilities
  • 5.5.1. Outpatient Facilities Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 5.6. Others
  • 5.6.1. Others Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Participant Overview
• 6.2. Company Market Position Analysis
• 6.3. Company Categorization
• 6.4. Strategy Mapping
• 6.5. Company Profiles/Listing
  • 6.5.1. Stryker Corporation
    • 6.5.1.1. Company Overview
    • 6.5.1.2. Financial Performance
    • 6.5.1.3. Product Benchmarking
    • 6.5.1.4. Strategic Initiatives
  • 6.5.2. Abbott Laboratories
    • 6.5.2.1. Company Overview
    • 6.5.2.2. Financial Performance
    • 6.5.2.3. Product Benchmarking
    • 6.5.2.4. Strategic Initiatives
  • 6.5.3. Medtronic plc
    • 6.5.3.1. Company Overview
    • 6.5.3.2. Financial Performance
    • 6.5.3.3. Product Benchmarking
    • 6.5.3.4. Strategic Initiatives
  • 6.5.4. Boston Scientific Corporation
    • 6.5.4.1. Company Overview
    • 6.5.4.2. Financial Performance
    • 6.5.4.3. Product Benchmarking
    • 6.5.4.4. Strategic Initiatives
  • 6.5.5. Avanos Medical, Inc
    • 6.5.5.1. Company Overview
    • 6.5.5.2. Financial Performance
    • 6.5.5.3. Product Benchmarking
    • 6.5.5.4. Strategic Initiatives
  • 6.5.6. Epimed International, Inc.
    • 6.5.6.1. Company Overview
    • 6.5.6.2. Financial Performance
    • 6.5.6.3. Product Benchmarking
    • 6.5.6.4. Strategic Initiatives
  • 6.5.7. Medline Inc.
    • 6.5.7.1. Company Overview
    • 6.5.7.2. Financial Performance
    • 6.5.7.3. Product Benchmarking
    • 6.5.7.4. Strategic Initiatives
  • 6.5.8. Elevaris Medical Devices
    • 6.5.8.1. Company Overview
    • 6.5.8.2. Financial Performance
    • 6.5.8.3. Product Benchmarking
    • 6.5.8.4. Strategic Initiatives